TY - JOUR
T1 - Current trend in translational research for treatment of ovarian cancer
AU - Ju, Woong
N1 - Publisher Copyright:
© Korean Medical Association.
PY - 2016/3
Y1 - 2016/3
N2 - Ovarian cancer is the most lethal gynecologic cancer. Countless efforts have been made to improve the survival of ovarian cancer patients by clinicians as well as basic researchers so far. As a result of those extensive translational researches some of promising molecular targets and its proper therapies are introduced into practice for treating intractable ovarian cancer, which includes anti-angiogenic therapy, tyrosine kinase inhibitor, and other modulators of cancer-related signaling pathways. Current trend of translational researches in ovarian cancer treatment are mainly focused on discovering companion diagnostics which can categorize the subgroup of patient having specific biomarker that may serve as a target of new treatment because the consequent outcome of new therapy varies depending on the molecular profile of each patient. It is important for clinician to consider each ovarian cancer patients to have a possible therapeutic target and to examine the tissue biopsies with available companion diagnostics. In addition more interest and endeavor should be given to the clinical trials to apply the result of up-to-date translational researches.
AB - Ovarian cancer is the most lethal gynecologic cancer. Countless efforts have been made to improve the survival of ovarian cancer patients by clinicians as well as basic researchers so far. As a result of those extensive translational researches some of promising molecular targets and its proper therapies are introduced into practice for treating intractable ovarian cancer, which includes anti-angiogenic therapy, tyrosine kinase inhibitor, and other modulators of cancer-related signaling pathways. Current trend of translational researches in ovarian cancer treatment are mainly focused on discovering companion diagnostics which can categorize the subgroup of patient having specific biomarker that may serve as a target of new treatment because the consequent outcome of new therapy varies depending on the molecular profile of each patient. It is important for clinician to consider each ovarian cancer patients to have a possible therapeutic target and to examine the tissue biopsies with available companion diagnostics. In addition more interest and endeavor should be given to the clinical trials to apply the result of up-to-date translational researches.
KW - Companion diagnostics
KW - Ovarian neoplasms
KW - Translational medical research
UR - http://www.scopus.com/inward/record.url?scp=84962232077&partnerID=8YFLogxK
U2 - 10.5124/jkma.2016.59.3.189
DO - 10.5124/jkma.2016.59.3.189
M3 - Article
AN - SCOPUS:84962232077
VL - 59
SP - 189
EP - 193
JO - Journal of the Korean Medical Association
JF - Journal of the Korean Medical Association
SN - 1975-8456
IS - 3
ER -